Anti-Spike IgG antibodies as correlates of protection against SARS-CoV-2 infection in the pre-Omicron and Omicron era.

Publication date: Aug 01, 2024

Anti-Spike IgG antibodies against SARS-CoV-2, which are elicited by vaccination and infection, are correlates of protection against infection with pre-Omicron variants. Whether this association can be generalized to infections with Omicron variants is unclear. We conducted a retrospective cohort study with 8457 blood donors in Tyrol, Austria, analyzing 15,340 anti-Spike IgG antibody measurements from March 2021 to December 2022 assessed by Abbott SARS-CoV-2 IgG II chemiluminescent microparticle immunoassay. Using a Bayesian joint model, we estimated antibody trajectories and adjusted hazard ratios for incident SARS-CoV-2 infection ascertained by self-report or seroconversion of anti-Nucleocapsid antibodies. At the time of their earliest available anti-Spike IgG antibody measurement (median November 23, 2021), participants had a median age of 46. 0 years (IQR 32. 8-55. 2), with 45. 3% being female, 41. 3% having a prior SARS-CoV-2 infection, and 75. 5% having received at least one dose of a COVID-19 vaccine. Among 6159 participants with endpoint data, 3700 incident SARS-CoV-2 infections with predominantly Omicron sublineages were recorded over a median of 8. 8 months (IQR 5. 7-12. 4). The age- and sex-adjusted hazard ratio for SARS-CoV-2 associated with having twice the anti-Spike IgG antibody titer was 0. 875 (95% credible interval 0. 868-0. 881) overall, 0. 842 (0. 827-0. 856) during 2021, and 0. 884 (0. 877-0. 891) during 2022 (all p 

Concepts Keywords
Antibodies Adult
Austria Antibodies, Viral
November Antibodies, Viral
Sex Austria
Bayes Theorem
Bayesian joint model
blood donors
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Humans
Immunoglobulin G
Immunoglobulin G
Male
Middle Aged
Retrospective Studies
SARS-CoV-2
Seroconversion
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2

Semantics

Type Source Name
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccination
disease MESH infection
disease IDO blood
disease VO report
disease MESH seroconversion
disease VO time
disease VO dose
disease VO COVID-19 vaccine
disease VO Glycoprotein

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *